Information provided in the product description is from published literature. Due to the nature of scientific experimentation, your results (e.g., selectivity and effective concentrations) or specific application for this product may differ. If you have questions about how this product fits your application, please contact our technical support staff.
Visit our FAQ
Toll Free Phone (USA and Canada Only): (888) 526-5351
Direct Phone: (734) 975-3888
Product Categories
Research Area
Provide batch numbers separated by commas to download or request available product inserts, QC sheets, certificates of analysis, data packs, and GC-MS data.
Roginolisib is an inhibitor of PI3Kδ (IC50 = 0.019 µM).1 It is selective for PI3Kδ over PI3Kα, PI3Kβ, PI3Kγ, VPS34, and PI3KC2β (IC50s = 0.43, 1.5, 10.3, 5.6, and 5.9 µM, respectively). Roginolisib inhibits the growth of SU-DHL-6 B cell lymphoma cells that endogenously express PI3Kδ (GI50 = 0.24 µM) but not cancer cell lines endogenously expressing PI3Kα, PI3Kβ, or PI3Kγ. In vivo, roginolisib (30 mg/kg twice daily) alone or in combination with an anti-PD-1 antibody slows tumor growth and decreases tumor volume in a murine Lewis lung carcinoma model.
WARNING This product is not for human or veterinary use.
1. IOA-